Skip to main content
Erschienen in: Journal of Neuro-Oncology 1/2019

12.11.2018 | Clinical Study

Survival of glioma patients in relation to mobile phone use in Denmark, Finland and Sweden

verfasst von: Ann Olsson, Liacine Bouaoun, Anssi Auvinen, Maria Feychting, Christoffer Johansen, Tiit Mathiesen, Beatrice Melin, Anna Lahkola, Suvi Larjavaara, Anne-Sophie Villegier, Graham Byrnes, Isabelle Deltour, Joachim Schüz

Erschienen in: Journal of Neuro-Oncology | Ausgabe 1/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Gliomas are the most common cancer of the brain, with a poor prognosis in particular for glioblastoma. In 2014, a study suggested reduced survival in relation to latency of mobile phone use among glioblastoma patients. A joint epidemiological/experimental project to study effects of RF-EMF on tumor development and progression was established. The current analysis relates to the epidemiological part and addresses whether pre-diagnostic mobile phone use was associated with survival among glioma patients.

Methods

Glioma cases (n = 806) previously enrolled in a collaborative population-based case–control study in Denmark, Finland and Sweden were followed up for survival. Vital status, date of death, date of emigration, or date last known to be alive was obtained based on registry linkages with a unique personal ID in each country. Cox regression models were used to calculate hazard ratios (HR) and 95% confidence intervals (CI) stratified by country. Covariates investigated were sex, age, education, histology, treatment, anatomic location and marital status.

Results

No indication of reduced survival among glioblastoma patients was observed for various measures of mobile phone use (ever regular use, time since start of regular use, cumulative call time overall or in the last 12 months) relative to no or non-regular use. All significant associations suggested better survival for mobile phone users. Results were similar for high-grade and low-grade gliomas.

Conclusions

We found no evidence of reduced survival among glioma patients in relation to previous mobile phone use.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Ervik M, Lam F, Ferley J, Mery L, Soerjomataram I, Bray F (2016) Cancer today. Lyon, France: International Agency for Research on Cancer. Cancer Today. http://gco.iarc.fr/today, Accessed 28 May 2018 Ervik M, Lam F, Ferley J, Mery L, Soerjomataram I, Bray F (2016) Cancer today. Lyon, France: International Agency for Research on Cancer. Cancer Today. http://​gco.​iarc.​fr/​today, Accessed 28 May 2018
5.
Zurück zum Zitat Melin BS, Barnholtz-Sloan JS, Wrensch MR, Johansen C, Il’yasova D, Kinnersley B, Ostrom QT, Labreche K, Chen Y, Armstrong G, Liu Y, Eckel-Passow JE, Decker PA, Labussiere M, Idbaih A, Hoang-Xuan K, Di Stefano AL, Mokhtari K, Delattre JY, Broderick P, Galan P, Gousias K, Schramm J, Schoemaker MJ, Fleming SJ, Herms S, Heilmann S, Nothen MM, Wichmann HE, Schreiber S, Swerdlow A, Lathrop M, Simon M, Sanson M, Andersson U, Rajaraman P, Chanock S, Linet M, Wang Z, Yeager M, Wiencke JK, Hansen H, McCoy L, Rice T, Kosel ML, Sicotte H, Amos CI, Bernstein JL, Davis F, Lachance D, Lau C, Merrell RT, Shildkraut J, Ali-Osman F, Sadetzki S, Scheurer M, Shete S, Lai RK, Claus EB, Olson SH, Jenkins RB, Houlston RS, Bondy ML (2017) Genome-wide association study of glioma subtypes identifies specific differences in genetic susceptibility to glioblastoma and non-glioblastoma tumors. Nat Genet 49:789–794. https://doi.org/10.1038/ng.3823 CrossRefPubMedPubMedCentral Melin BS, Barnholtz-Sloan JS, Wrensch MR, Johansen C, Il’yasova D, Kinnersley B, Ostrom QT, Labreche K, Chen Y, Armstrong G, Liu Y, Eckel-Passow JE, Decker PA, Labussiere M, Idbaih A, Hoang-Xuan K, Di Stefano AL, Mokhtari K, Delattre JY, Broderick P, Galan P, Gousias K, Schramm J, Schoemaker MJ, Fleming SJ, Herms S, Heilmann S, Nothen MM, Wichmann HE, Schreiber S, Swerdlow A, Lathrop M, Simon M, Sanson M, Andersson U, Rajaraman P, Chanock S, Linet M, Wang Z, Yeager M, Wiencke JK, Hansen H, McCoy L, Rice T, Kosel ML, Sicotte H, Amos CI, Bernstein JL, Davis F, Lachance D, Lau C, Merrell RT, Shildkraut J, Ali-Osman F, Sadetzki S, Scheurer M, Shete S, Lai RK, Claus EB, Olson SH, Jenkins RB, Houlston RS, Bondy ML (2017) Genome-wide association study of glioma subtypes identifies specific differences in genetic susceptibility to glioblastoma and non-glioblastoma tumors. Nat Genet 49:789–794. https://​doi.​org/​10.​1038/​ng.​3823 CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat McCarthy BJ, Rankin KM, Aldape K, Bondy ML, Brannstrom T, Broholm H, Feychting M, Il’yasova D, Inskip PD, Johansen C, Melin BS, Ruder AM, Butler MA, Scheurer ME, Schuz J, Schwartzbaum JA, Wrensch MR, Davis FG (2011) Risk factors for oligodendroglial tumors: a pooled international study. Neuro Oncol 13:242–250. https://doi.org/10.1093/neuonc/noq173 CrossRefPubMed McCarthy BJ, Rankin KM, Aldape K, Bondy ML, Brannstrom T, Broholm H, Feychting M, Il’yasova D, Inskip PD, Johansen C, Melin BS, Ruder AM, Butler MA, Scheurer ME, Schuz J, Schwartzbaum JA, Wrensch MR, Davis FG (2011) Risk factors for oligodendroglial tumors: a pooled international study. Neuro Oncol 13:242–250. https://​doi.​org/​10.​1093/​neuonc/​noq173 CrossRefPubMed
8.
11.
Zurück zum Zitat Feychting M, Schuz J (2017) 15—Electromagnetic fields. In: Thun M, Linet MS, Cerhan JR, Haiman CA, Schottenfeld D (eds) Cancer epidemiology and prevention. 4th edn. Oxford Scholarship Online, Oxford Feychting M, Schuz J (2017) 15—Electromagnetic fields. In: Thun M, Linet MS, Cerhan JR, Haiman CA, Schottenfeld D (eds) Cancer epidemiology and prevention. 4th edn. Oxford Scholarship Online, Oxford
13.
Zurück zum Zitat IARC Working Group on the Evaluation of Carcinogenic Risks to Humans (2011) Non-ionizing radiation, Part II: radiofrequency electromagnetic fields, IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, Lyon IARC Working Group on the Evaluation of Carcinogenic Risks to Humans (2011) Non-ionizing radiation, Part II: radiofrequency electromagnetic fields, IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, Lyon
15.
16.
Zurück zum Zitat Eckel-Passow JE, Lachance DH, Molinaro AM, Walsh KM, Decker PA, Sicotte H, Pekmezci M, Rice T, Kosel ML, Smirnov IV, Sarkar G, Caron AA, Kollmeyer TM, Praska CE, Chada AR, Halder C, Hansen HM, McCoy LS, Bracci PM, Marshall R, Zheng S, Reis GF, Pico AR, O’Neill BP, Buckner JC, Giannini C, Huse JT, Perry A, Tihan T, Berger MS, Chang SM, Prados MD, Wiemels J, Wiencke JK, Wrensch MR, Jenkins RB (2015) Glioma groups based on 1p/19q, IDH, and TERT Promoter mutations in tumors. N Engl J Med 372:2499–2508. https://doi.org/10.1056/NEJMoa1407279 CrossRefPubMedPubMedCentral Eckel-Passow JE, Lachance DH, Molinaro AM, Walsh KM, Decker PA, Sicotte H, Pekmezci M, Rice T, Kosel ML, Smirnov IV, Sarkar G, Caron AA, Kollmeyer TM, Praska CE, Chada AR, Halder C, Hansen HM, McCoy LS, Bracci PM, Marshall R, Zheng S, Reis GF, Pico AR, O’Neill BP, Buckner JC, Giannini C, Huse JT, Perry A, Tihan T, Berger MS, Chang SM, Prados MD, Wiemels J, Wiencke JK, Wrensch MR, Jenkins RB (2015) Glioma groups based on 1p/19q, IDH, and TERT Promoter mutations in tumors. N Engl J Med 372:2499–2508. https://​doi.​org/​10.​1056/​NEJMoa1407279 CrossRefPubMedPubMedCentral
20.
Zurück zum Zitat Sjostrom S, Andersson U, Liu Y, Brannstrom T, Broholm H, Johansen C, Collatz-Laier H, Henriksson R, Bondy M, Melin B (2010) Genetic variations in EGF and EGFR and glioblastoma outcome. Neuro Oncol 12:815–821CrossRefPubMedPubMedCentral Sjostrom S, Andersson U, Liu Y, Brannstrom T, Broholm H, Johansen C, Collatz-Laier H, Henriksson R, Bondy M, Melin B (2010) Genetic variations in EGF and EGFR and glioblastoma outcome. Neuro Oncol 12:815–821CrossRefPubMedPubMedCentral
23.
Zurück zum Zitat Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40:373–383CrossRef Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40:373–383CrossRef
24.
Zurück zum Zitat Deyo RA, Cherkin DC, Ciol MA (1992) Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 45:613–619CrossRefPubMed Deyo RA, Cherkin DC, Ciol MA (1992) Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 45:613–619CrossRefPubMed
25.
Zurück zum Zitat Cardis E, Richardson L, Deltour I, Armstrong B, Feychting M, Johansen C, Kilkenny M, McKinney P, Modan B, Sadetzki S, Schuz J, Swerdlow A, Vrijheid M, Auvinen A, Berg G, Blettner M, Bowman J, Brown J, Chetrit A, Christensen HC, Cook A, Hepworth S, Giles G, Hours M, Iavarone I, Jarus-Hakak A, Klaeboe L, Krewski D, Lagorio S, Lonn S, Mann S, McBride M, Muir K, Nadon L, Parent ME, Pearce N, Salminen T, Schoemaker M, Schlehofer B, Siemiatycki J, Taki M, Takebayashi T, Tynes T, van Tongeren M, Vecchia P, Wiart J, Woodward A, Yamaguchi N (2007) The INTERPHONE study: design, epidemiological methods, and description of the study population. Eur J Epidemiol 22:647–664. https://doi.org/10.1007/s10654-007-9152-z CrossRefPubMed Cardis E, Richardson L, Deltour I, Armstrong B, Feychting M, Johansen C, Kilkenny M, McKinney P, Modan B, Sadetzki S, Schuz J, Swerdlow A, Vrijheid M, Auvinen A, Berg G, Blettner M, Bowman J, Brown J, Chetrit A, Christensen HC, Cook A, Hepworth S, Giles G, Hours M, Iavarone I, Jarus-Hakak A, Klaeboe L, Krewski D, Lagorio S, Lonn S, Mann S, McBride M, Muir K, Nadon L, Parent ME, Pearce N, Salminen T, Schoemaker M, Schlehofer B, Siemiatycki J, Taki M, Takebayashi T, Tynes T, van Tongeren M, Vecchia P, Wiart J, Woodward A, Yamaguchi N (2007) The INTERPHONE study: design, epidemiological methods, and description of the study population. Eur J Epidemiol 22:647–664. https://​doi.​org/​10.​1007/​s10654-007-9152-z CrossRefPubMed
29.
Zurück zum Zitat Wessels PH, Weber WE, Raven G, Ramaekers FC, Hopman AH, Twijnstra A (2003) Supratentorial grade II astrocytoma: biological features and clinical course. Lancet Neurol 2:395–403CrossRefPubMed Wessels PH, Weber WE, Raven G, Ramaekers FC, Hopman AH, Twijnstra A (2003) Supratentorial grade II astrocytoma: biological features and clinical course. Lancet Neurol 2:395–403CrossRefPubMed
31.
Zurück zum Zitat Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996. https://doi.org/10.1056/NEJMoa043330 CrossRef Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996. https://​doi.​org/​10.​1056/​NEJMoa043330 CrossRef
32.
Zurück zum Zitat Vrijheid M, Armstrong BK, Bedard D, Brown J, Deltour I, Iavarone I, Krewski D, Lagorio S, Moore S, Richardson L, Giles GG, McBride M, Parent ME, Siemiatycki J, Cardis E (2009) Recall bias in the assessment of exposure to mobile phones. J Exp Sci Environ Epidemiol 19:369–381. https://doi.org/10.1038/jes.2008.27 CrossRef Vrijheid M, Armstrong BK, Bedard D, Brown J, Deltour I, Iavarone I, Krewski D, Lagorio S, Moore S, Richardson L, Giles GG, McBride M, Parent ME, Siemiatycki J, Cardis E (2009) Recall bias in the assessment of exposure to mobile phones. J Exp Sci Environ Epidemiol 19:369–381. https://​doi.​org/​10.​1038/​jes.​2008.​27 CrossRef
Metadaten
Titel
Survival of glioma patients in relation to mobile phone use in Denmark, Finland and Sweden
verfasst von
Ann Olsson
Liacine Bouaoun
Anssi Auvinen
Maria Feychting
Christoffer Johansen
Tiit Mathiesen
Beatrice Melin
Anna Lahkola
Suvi Larjavaara
Anne-Sophie Villegier
Graham Byrnes
Isabelle Deltour
Joachim Schüz
Publikationsdatum
12.11.2018
Verlag
Springer US
Erschienen in
Journal of Neuro-Oncology / Ausgabe 1/2019
Print ISSN: 0167-594X
Elektronische ISSN: 1573-7373
DOI
https://doi.org/10.1007/s11060-018-03019-5

Weitere Artikel der Ausgabe 1/2019

Journal of Neuro-Oncology 1/2019 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Neu im Fachgebiet Neurologie

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.